MAPT and Alzheimer disease: Interestingly, in our cohort plasma Aβ peptides or the Aβ1–42/1–40 ratio did not associate to any of the core CSF AD biomarkers, in contrast to the previously reported positive association between plasma P-tau181 and CSF tau biomarkers in the same cohort [29].